Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Expanded Access
Expanded Access
No longer available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
California
-
San Diego, California, United States, 92123
- Children's Hospital
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Children's Hospital
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Orlando, Florida, United States, 32806
- Arnold Palmer Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University School of Medicine
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Louisana State University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- New England Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University Medical Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Children's Hospital UN/CU)
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
Rochester, New York, United States, 14642
- Childrens Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, United States, 75235
- University of Texas
-
Fort Worth, Texas, United States, 76104
- Cook Children's Heart Center
-
-
Virginia
-
Norfolk, Virginia, United States, 30322
- Children's Hospital of The King's Daughters
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53201
- Children's Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a demonstrated patent ductus arteriosus
- Body weight > 5 Kilograms
Exclusion Criteria:
- Pulmonary vascular resistance above 8 Woods units or a Rp/Rs >0.4.
- Additional cardiac or non-cardiac abnormality that can reasonably be expected to significantly affect the patient's health adversely in the next two years, i.e.: cancer, Eisenmenger's syndrome, other serious congenital heart disease.
- Pelvic vein or inferior vena cava thrombosis
- Sepsis (local/generalized) or any type of infection that cannot be successfully treated prior to device placement.
- History of repeated pulmonary infection
- Demonstrated intracardiac thrombi on echocardiography • Inability to obtain informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: implant to close PDA
|
Device closure with AMPLATZER Duct Occluder
Compare results of device closure to objective performance criteria
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reporting of Late Adverse Events Relating to the Device.
Time Frame: Long term follow up for data captured at 5, 6 or 7 years post implant
|
Long term follow up for data captured at 5, 6 or 7 years post implant
|
|
|
Reporting of Late Efficacy Issues Regarding Patent Ductus Arteriosis (PDA) Closure
Time Frame: Long term follow up data captured at 5, 6 or 7 years post implant
|
The number of participants with a residual shunt (efficacy)
|
Long term follow up data captured at 5, 6 or 7 years post implant
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AGA-004
- G980103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.